These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 39421179)

  • 1. Impact of obesity on survival outcomes of women with advanced epithelial ovarian cancer in Lagos, Nigeria: a retrospective cohort study.
    Okunade KS; Akinmola OO; Adekanye TV; Packson A; Adelabu H; Thomas-Ogodo O; Okoro AC; Okoye C; Anorlu RI
    Ecancermedicalscience; 2024; 18():1743. PubMed ID: 39421179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes following interval versus primary debulking surgery in advanced epithelial ovarian cancer: A retrospective cohort study in Lagos, Southwest Nigeria.
    Okunade KS; Adekanye TV; Osunwusi B; Soibi-Harry A; Okoro AC; Toks-Omage E; Okunowo AA; Ohazurike EO; Anorlu RI
    Res Sq; 2024 Jan; ():. PubMed ID: 38260667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
    Okunade KS; Dawodu O; Adenekan M; Nwogu CM; Awofeso O; Ugwu AO; Salako O; John-Olabode S; Olowoselu OF; Anorlu RI
    Niger J Clin Pract; 2020 Aug; 23(8):1141-1147. PubMed ID: 32788493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria.
    Okunade KS; Adejimi AA; Ohazurike EO; Salako O; Osunwusi B; Adenekan MA; Ugwu AO; Soibi-Harry A; Dawodu O; Okunowo AA; Anorlu RI; Berek JS
    JCO Glob Oncol; 2021 Jan; 7():89-98. PubMed ID: 33449803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of body weight on ovarian cancer outcomes.
    Backes FJ; Nagel CI; Bussewitz E; Donner J; Hade E; Salani R
    Int J Gynecol Cancer; 2011 Dec; 21(9):1601-5. PubMed ID: 21997171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity and survival in advanced non-small cell lung cancer patients treated with chemotherapy, immunotherapy, or chemoimmunotherapy: a multicenter cohort study.
    Nie W; Lu J; Qian J; Wang SY; Cheng L; Zheng L; Tao GY; Zhang XY; Chu TQ; Han BH; Zhong H
    BMC Med; 2024 Oct; 22(1):463. PubMed ID: 39402614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
    Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
    Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum vitamin D deficiency and risk of epithelial ovarian cancer in Lagos, Nigeria.
    Sajo EA; Okunade KS; Olorunfemi G; Rabiu KA; Anorlu RI
    Ecancermedicalscience; 2020; 14():1078. PubMed ID: 32863872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of lnc-MyD88 and its relationship with the prognosis of patients with epithelial ovarian cancer].
    Zhu Y; Huang JM; Zhang GN; Li JM; Huang J
    Zhonghua Fu Chan Ke Za Zhi; 2022 Feb; 57(2):117-124. PubMed ID: 35184472
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of body mass index on survival and serious adverse events in advanced non-small cell lung cancer treated with bevacizumab: a meta-analysis of randomized clinical trials.
    Shukla S; Babcock Z; Pizzi L; Brunetti L
    Curr Med Res Opin; 2021 May; 37(5):811-817. PubMed ID: 33685311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of body mass index on survival in advanced epithelial ovarian cancer.
    Bae HS; Hong JH; Ki KD; Song JY; Shin JW; Lee JM; Lee JK; Lee NW; Lee C; Lee KW; Kim YM
    J Korean Med Sci; 2014 Jun; 29(6):793-7. PubMed ID: 24932080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer.
    Yu W; Ye Z; Fang X; Jiang X; Jiang Y
    J Ovarian Res; 2019 Sep; 12(1):88. PubMed ID: 31533857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between BMI and oncologic outcomes in epithelial ovarian cancer: a predictors-matched case-control study.
    Levin G; Brezinov Y; Tzur Y; Bar-Noy T; Brodeur MN; Salvador S; Lau S; Gotlieb W
    Arch Gynecol Obstet; 2024 Jul; 310(1):587-593. PubMed ID: 38714562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.
    Mardas M; Stelmach-Mardas M; Madry R
    Support Care Cancer; 2017 Mar; 25(3):795-800. PubMed ID: 27771784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes mellitus and ovarian cancer: more complex than just increasing risk.
    Shah MM; Erickson BK; Matin T; McGwin G; Martin JY; Daily LB; Pasko D; Haygood CW; Fauci JM; Leath CA
    Gynecol Oncol; 2014 Nov; 135(2):273-7. PubMed ID: 25220626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
    Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk predictors of early recurrence in women with epithelial ovarian cancer in Lagos, Nigeria.
    Okunade KS; Adetuyi IE; Adenekan M; Ohazurike E; Anorlu RI
    Pan Afr Med J; 2020; 36():272. PubMed ID: 33088401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    Wuntakal R; Seshadri S; Montes A; Lane G
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.